0001567619-20-012131.txt : 20200615 0001567619-20-012131.hdr.sgml : 20200615 20200615151540 ACCESSION NUMBER: 0001567619-20-012131 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200611 FILED AS OF DATE: 20200615 DATE AS OF CHANGE: 20200615 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Smither John W CENTRAL INDEX KEY: 0001559583 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39186 FILM NUMBER: 20963061 MAIL ADDRESS: STREET 1: C/O KYTHERA BIOPHARMACEUTICALS, INC. STREET 2: 27200 WEST AGOURA ROAD, SUITE 200 CITY: CALABASAS STATE: CA ZIP: 91301 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Arcutis Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001787306 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 812974255 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2945 TOWNSGATE ROAD STREET 2: SUITE 110 CITY: WESTLAKE VILLAGE STATE: CA ZIP: 91361 BUSINESS PHONE: 805-418-5006 MAIL ADDRESS: STREET 1: 2945 TOWNSGATE ROAD STREET 2: SUITE 110 CITY: WESTLAKE VILLAGE STATE: CA ZIP: 91361 FORMER COMPANY: FORMER CONFORMED NAME: Arcutis, Inc. DATE OF NAME CHANGE: 20190905 4 1 doc1.xml FORM 4 X0306 4 2020-06-11 0 0001787306 Arcutis Biotherapeutics, Inc. ARQT 0001559583 Smither John W C/O ARCUTIS BIOTHERAPEUTICS, INC. 2945 TOWNSGATE ROAD, SUITE 110 WESTLAKE VILLAGE CA 91361 0 1 0 0 Chief Financial Officer Common Stock 2020-06-11 4 M 0 14875 1.6806 A 123840 D Stock Option (Right to Buy) 1.6806 2020-06-11 4 M 0 14875 0 D 2029-05-14 Common Stock 14875 110080 D Reflects cash exercise of stock option without the disposition of the underlying shares. Includes 9,000 Restricted Stock Units ("RSUs"). The RSUs vest annually in equal installments over a period of 4 years commencing on the grant date, so that 100% of the RSUs become fully vested on February 27, 2024. The option vests as to 1/4 of the total shares on May 1, 2020, and then 1/48 of the total shares vest monthly thereafter, with 100% of the total shares vested and exercisable on May 1, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. /s/ John W. Smither 2020-06-15